Evidence map›Paper›PMID 41629446›Full record

ArticleScientific reports2026

Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection.

Jason R Smith, Ayelen Toro, Agustina Sabater, Suzana Kovacic, Fuqiang Ban, Ana P Arevalo, Martina Crispo, Geraldine Gueron, Robert N Young, Artem Cherkasov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jason R SmithDepartment of Urologic Science, Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, B.C., V6H3Z6, Canada. jsmith@prostatecentre.com.
Ayelen ToroDepartamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires C1428EGA, Argentina.
Agustina SabaterDepartamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires C1428EGA, Argentina.
Suzana KovacicDepartment of Chemistry, Simon Fraser University, Burnaby, B.C., V5A1S6, Canada.
Fuqiang BanDepartment of Urologic Science, Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, B.C., V6H3Z6, Canada.
Ana P ArevaloLaboratory Animal Biotechnology Unit (UBAL), Mataojo 2020, Institut Pasteur de Montevideo, 11400, Montevideo, Uruguay.
Martina CrispoLaboratory Animal Biotechnology Unit (UBAL), Mataojo 2020, Institut Pasteur de Montevideo, 11400, Montevideo, Uruguay.
Geraldine GueronDepartamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires C1428EGA, Argentina.
Robert N YoungDepartment of Chemistry, Simon Fraser University, Burnaby, B.C., V5A1S6, Canada.
Artem CherkasovDepartment of Urologic Science, Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, B.C., V6H3Z6, Canada. acherkasov@prostatecentre.com.

Funding

British Columbia Knowledge Development Fund 36194Canada Research Chairs CRC-2020-00007CIHR VR3-172639Fondo para la Convergencia Estructural del Mercosur COF 03/11
6 · The paper itself

Abstract

Herein we report the development of novel covalent inhibitors of the SARS-CoV-2 main protease (Mpro). The developed compounds VPC285785 and VPC285786 demonstrated moderate inhibition of Mpro (IC

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentProtease InhibitorsSARS-CoV-2Administration, OralAnimalsAzabicyclo CompoundsCathepsin LCoronavirus 3C ProteasesCOVID-19Disease Models, AnimalFemaleHumansMaleMicePyrrolidinonesAntiviral AgentsAzabicyclo CompoundsCathepsin LCoronavirus 3C ProteasesnirmatrelvirProtease InhibitorsPyrrolidinones

Identifiers

PMID41629446
PMCPMC12916759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.